Physician profile
Clinton L Seifert
NPI 1306041801
$2,605.51
in general payments reported to CMS, 2019-2025
41 companies · $821 in 2025
The $821 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.95 · 2020: $60.61 · 2021: $498 · 2022: $394 · 2023: $265 · 2024: $557 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273 · Long Term Medical Supply Or Device Loan: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.50 |
| Long Term Medical Supply Or Device Loan | $370.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $370.36 | 2025 | Pentax Medical, Sony |
| Abbvie INC. | $306.62 | 2021-2024 | Qulipta, Ubrelvy |
| Medtronic, INC. | $220.12 | 2022-2025 | Maxtack |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.77 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Teva Pharmaceuticals USA, INC. | $196.83 | 2020-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.98 | 2021-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.92 | 2023-2024 | Caplyta |
| Novo Nordisk INC | $97.83 | 2023-2024 | Wegovy |
| Vertex Pharmaceuticals Incorporated | $85.51 | 2024-2025 | |
| Kerecis Limited | $70.78 | 2021-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Dexcom, INC. | $54.40 | 2022-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $52.35 | 2020-2021 | |
| Janssen Biotech, INC. | $46.82 | 2025 | Tremfya |
| Qol Medical, LLC | $42.44 | 2025 | Sucraid |
| Heron Therapeutics, INC. | $39.82 | 2024 | Zynrelef, Aponvie |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Seifert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.